Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) EPS (Weighted Average and Diluted) (2020 - 2026)

Alx Oncology Holdings' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.92 for Q4 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 22.67% to -$0.92 in Q4 2023 year-over-year; TTM through Dec 2023 was -$3.74, a 23.43% decrease, with the full-year FY2025 number at -$1.9, up 26.36% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.92 in Q4 2023 for Alx Oncology Holdings, up from -$1.24 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ALXO hit a ceiling of -$0.4 in Q2 2021 and a floor of -$1.24 in Q3 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.79 across 4 years, with a median of -$0.78 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 31.08% in 2021 and later plummeted 102.5% in 2022.
  • Tracing ALXO's EPS (Weighted Average and Diluted) over 4 years: stood at -$1.02 in 2020, then skyrocketed by 31.08% to -$0.7 in 2021, then dropped by 7.14% to -$0.75 in 2022, then decreased by 22.67% to -$0.92 in 2023.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ALXO at -$0.92 in Q4 2023, -$1.24 in Q3 2023, and -$0.84 in Q2 2023.